EULAR: Identify Arthritis Early, Treat it Effectively

Dr. Martini noted the start of PharmaChild, a European initiative to follow, long-term, thousands of JIA patients on biological agents. “Only long-term observation on many thousands of patients can establish the safety of a drug,” he said.

Thomas Collins is a freelance medical writer based in Florida.

References

1. Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012:44:291-296.
2. Scher JU, Ubeda C, Equinda M, et al. Odontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum. 2012 May 10. [Epub ahead of print.]
3. Källberg H, Ding B, Padyukov L, et al. Smoking is a major preventable risk factor for rheumatoid arthritis: Estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis. 2011;70:508-511.
4. Demoruelle MK, Weisman MH, Simonian PL, et al. Brief report: Airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: Early injury or initiating site of autoimmunity? Arthritis Rheum. 2012:64;1756-1764.
5. Boldin MP, Taganov KD, Rao DS, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med. 2011;208:1189-1201.
6. Blüml S, Bonelli M, Niederreiter B, et al. Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum. 2011;62:1281-1288.
7. Nordal E, Zak M, Aalto K, et al. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:2809-2818.
8. Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: A randomized clinical trial. JAMA. 2010;303:1266-1273.
9. Wittkowski H, Kuemmerle-Deschner JB, Austermann J, et al. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. Ann Rheum Dis. 2011;70: 2075-2081.
10. Bulatović M, Heijstek MW, Verkaaik M, et al. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: Development and validation of a methotrexate intolerance severity score. Arthritis Rheum. 2011;63:2007-2013.
11. Otten MH, Prince FH, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011;306:2340-2347.
12. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: Forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010;62:2517-2524.
13. Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64:1263-1271.